
Home » FDA APPROVES EXELON FOR DEMENTIA IN PARKINSON'S DISEASE
FDA APPROVES EXELON FOR DEMENTIA IN PARKINSON'S DISEASE
June 28, 2006
The FDA has approved Swiss drugmaker Novartis' Exelon for the treatment of mild-to-moderate dementia associated with Parkinson's disease. The medication was previously approved for the treatment of mild-to-moderate dementia caused by Alzheimer's disease.
The new approval is based on the results of a randomized clinical trial in which Exelon was shown to be significantly more efficacious than placebo in 541 Parkinson's disease patients with dementia.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
19Jan
-
21Jan
-
26Jan
-
27Jan
-
27Jan
-
09Feb